Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'3'-cGAM(PS)2 is a **synthetic bisphosphorothioate analog** of the endogenous cyclic dinucleotide (CDN) 2'3'-cGAMP, designed to be more stable and potent than the natural ligand. It acts primarily as a **STING (stimulator of interferon genes) pathway agonist**, inducing **type I interferon production** and thereby influencing innate immune responses[1][2][5]. In addition to canonical STING-mediated effects, recent studies indicate that 2'3'-cGAM(PS)2—and 2'3'-cGAMP generally—can robustly promote cell migration in certain cancer cells through a **STING-independent pathway** involving direct activation of the small GTPase Rab18, leading to downstream induction of the transcription factor FosB[3][4]. The bisphosphorothioate modification prevents rapid enzymatic degradation, enhancing the molecule’s stability for research and potential therapeutic applications[2]. Main uses are in immunotherapy research and mechanistic studies involving innate immunity and cell migration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'3'-cGAM(PS)2.